SCHEMBL13635

SCHEMBL13635

COC(=O)/C(C)=C/c1cc2cc(Br)ccc2nc1NCc1ccc(OC)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
MAPT P10636 3/20 0.43
GAA P10253 2/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
TP53 P04637 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
CTNNB1 P35222 1/20 0.40
TCF7L2 Q9NQB0 1/20 0.40
PRUNE1 Q86TP1 1/20 0.40
POLB P06746 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39
EGFR P00533 3/20 0.38
ALDH1A1 P00352 2/20 0.38
APP P05067 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
VNN1 O95497 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8775 0.93 MAPT (0.42) MEN1KMT2AMAPTGAANPC1
SCHEMBL8776 0.93 MAPT (0.42) MEN1KMT2AMAPTGAANPC1
SCHEMBL9404 0.92 MEN1 (0.43) MEN1KMT2AMAPTGAANPC1
SCHEMBL9405 0.92 MEN1 (0.43) MEN1KMT2AMAPTGAANPC1
SCHEMBL9314 0.85 MEN1 (0.48) MEN1KMT2AMAPTGAANPC1
SCHEMBL14321926 0.84 ALDH1A1 (0.39) MEN1KMT2AMAPTGAANPC1
SCHEMBL14321924 0.84 ALDH1A1 (0.39) MEN1KMT2AMAPTGAANPC1
SCHEMBL13644 0.84 MAPT (0.43) MEN1KMT2AMAPTGAANPC1
SCHEMBL9775 0.84 POLB (0.47) MEN1KMT2AMAPTGAANPC1
SCHEMBL8834 0.84 POLB (0.47) MEN1KMT2AMAPTGAANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9296698-B2 Amino heteroaryl compounds as beta-secretase modulators and methods of use AMGEN INC. (US) 2016-03-29 US disclosed
US-9296698-B2 Amino heteroaryl compounds as beta-secretase modulators and methods of use AMGEN INC. (US) 2016-03-29 US disclosed
US-20120329830-A1 Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use AMGEN INC. (US) 2012-12-27 US disclosed
US-20120329830-A1 Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use AMGEN INC. (US) 2012-12-27 US disclosed
WO-2011063233-A1 AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2011-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329830-A1 Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use BACE1, BACE2, APP MEN1 4400/4885KMT2A 1441/4885MAPT 809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.